Shanghai Haoyuan Chemexpress Co. Ltd. A - Asset Resilience Ratio
Shanghai Haoyuan Chemexpress Co. Ltd. A (688131) has an Asset Resilience Ratio of 1.37% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2022–2025)
This chart shows how Shanghai Haoyuan Chemexpress Co. Ltd. A's Asset Resilience Ratio has changed over time. See financial flexibility index of Shanghai Haoyuan Chemexpress Co. Ltd. A to measure the company's free cash flow as a share of total liabilities.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Haoyuan Chemexpress Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688131 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥89.00 Million | 1.37% |
| Total Liquid Assets | CN¥89.00 Million | 1.37% |
Asset Resilience Insights
- Limited Liquidity: Shanghai Haoyuan Chemexpress Co. Ltd. A maintains only 1.37% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Haoyuan Chemexpress Co. Ltd. A Industry Peers by Asset Resilience Ratio
Compare Shanghai Haoyuan Chemexpress Co. Ltd. A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
JW Pharmaceutical Corp
KO:001067 |
Drug Manufacturers - Specialty & Generic | 8.17% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Guilin Sanjin Pharmaceutical Co Ltd
SHE:002275 |
Drug Manufacturers - Specialty & Generic | 14.80% |
|
Fuan Pharmaceutical Group Co
SHE:300194 |
Drug Manufacturers - Specialty & Generic | 1.34% |
|
DRI Healthcare Trust
TO:DHT-U |
Drug Manufacturers - Specialty & Generic | 13.91% |
|
Hainan Shuangcheng Pharmaceut
SHE:002693 |
Drug Manufacturers - Specialty & Generic | 1.03% |
Annual Asset Resilience Ratio for Shanghai Haoyuan Chemexpress Co. Ltd. A (2022–2025)
The table below shows the annual Asset Resilience Ratio data for Shanghai Haoyuan Chemexpress Co. Ltd. A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.32% | CN¥20.07 Million ≈ $2.94 Million |
CN¥6.29 Billion ≈ $921.05 Million |
-7.84pp |
| 2024-12-31 | 8.16% | CN¥449.15 Million ≈ $65.72 Million |
CN¥5.50 Billion ≈ $805.55 Million |
+7.68pp |
| 2022-12-31 | 0.48% | CN¥17.23 Million ≈ $2.52 Million |
CN¥3.60 Billion ≈ $526.46 Million |
-- |
About Shanghai Haoyuan Chemexpress Co. Ltd. A
Shanghai Haoyuan Chemexpress Co., Ltd. researches, develops, and manufactures pharmaceutical intermediates and small molecule drugs. The company offers APIs and API intermediates, vitamin D series compounds, CRO building blocks, and CRO life bioscience compounds. The company was founded in 2006 and is headquartered in Shanghai, China.